Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its...
Amoy Diagnostics Receives NMPA Approval for MSI Detection Kit as Companion Diagnostic for Immunotherapy
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in the Chinese diagnostics industry,...
Gaush Meditech Ltd Receives NMPA Approval for Rigid Corneal Contact Lens
Gaush Meditech Ltd (HKG: 2407), a company based in Suzhou, has announced that it has...
Wuhan Hiteck Biological Pharma Receives NMPA Approval for Aponermin in Multiple Myeloma Treatment
Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that...
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...
EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting
Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...
We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development
Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...
Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation
The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...
Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials
Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...
Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China
The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...